?-methyl-p-tyrosine in malignant pheochromocytoma

Amery, A; Moerman, E; Bossaert, H; Schaepdryver, A.F. De

doi:10.1007/bf00456942

Cited by 9 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials have shown metyrosine to suppress catecholamine synthesis and improve symptoms of catecholamine excess, including hypertension [11][12][13][14][15][16]. Metyrosine (DEMSER ® ) received United States Food and Drug Administration (USFDA) approval in 1979 for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma [17].…”

mentioning

confidence: 99%

Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan

et al. 2018

View full text Add to dashboard Cite

Abstract. To assess the efficacy, safety, and pharmacokinetics of metyrosine (an inhibitor of catecholamine synthesis) in patients with pheochromocytoma/paraganglioma (PPGL), we conducted a prospective, multi-center, open-label study at 11 sites in Japan. We recruited PPGL patients aged ≥12 years requiring preoperative or chronic treatment, receiving α-blocker treatment, having baseline urinary metanephrine (uMN) or normetanephrine (uNMN) levels ≥3 times the upper limit of normal values, and having symptoms associated with excess catecholamine. Metyrosine treatment was started at 500 mg/day and modified according to dose-adjustment criteria up to 4,000 mg/day. The main outcome measure was the proportion of patients who achieved at least 50% reduction in uMN or uNMN levels from baseline. Sixteen patients (11 males/5 females) aged 12-86 years participated. After 12 weeks of treatment and at the last evaluation of efficacy, the primary endpoint was achieved in 31.3% of all patients, including 66.7% of those under preoperative treatment and 23.1% of those under chronic treatment. Sedation, anemia, and death were reported in 1 patient each as serious adverse drug reactions during the 24-week treatment. Metyrosine was shown to be tolerated and to relieve symptoms by reducing excess catecholamine in PPGL patients under both preoperative and chronic treatment.

show abstract

mentioning

confidence: 99%